The Experimental and Developmental Therapeutics (EDT) program of the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA) is focused on improving the therapy of cancer through innovative pre-clinical and clinical research. The activities within this program span the range of experimental and developmental therapeutics from initial target discovery to regulatory approval for new treatments. This program identifies new therapeutic targets for cancer, new therapies and approaches directed at these targets, and has the expertise to help translate discoveries. The EDT program facilitates the assessment of novel therapies by fostering collaboration between pre-clinical and clinical researchers ultimately to provide patients with the best possible treatments. Key themes within EDT include: 1) identification of novel therapeutic targets, 2) synthesis and pre-clinical assessment of new compounds directed at specific targets and 3) preclinical assessment of compounds in novel cancer situations. The integration in December 2007 of UTHSCSA's cancer-focused resources with those of the CTRC's Institute for Drug Development (IDD) has allowed a greater emphasis on the efficient translation of preclinical research into eariy phase clinical studies within the EDT program and will allow rapid further Phase 11/111 exploration of promising approaches. The EDT program has 31 scientific members representing 8 departments from the School of Medicine, the Graduate School of Biomedical Sciences, and important components of the CTRC at UTHSCSA including the IDD and the Greehey Children's Cancer Research Institute. EDT program members currently receive $5.55 million (direct costs) annually in peer-reviewed grants from the NCI, NIH, FDA, and Department of Defense. Training is a very important component of the EDT program's activities. Program members train fellows and graduate students in pre-clinical and clinical departments. The IDD's Advanced Oncology/Hematology Drug Development Fellowship is a unique training program for physicians that focuses specifically on the multidisciplinary nature of anti-cancer therapy development. In summary, the EDT program is a highly integrated multidisciplinary collaborative effort between pre-clinical and clinical scientists, all focused on providing newer, better-targeted and more effective treatments for patients with cancer

Public Health Relevance

The Experimental and Developmental Therapeutics (EDT) Program is the keystone of the CTRC at UTHSCSA's effort to develop and test new treatments for cancer. It is a highly integrated multidisciplinary collaborative effort between diverse disciplines of pre-clinical and clinical scientists, all of whom are focused on improving the prognosis of patients with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA054174-18
Application #
8107441
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
18
Fiscal Year
2010
Total Cost
$37,718
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :
Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179
Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:
Du, Liqin; Zhao, Zhenze; Suraokar, Milind et al. (2018) LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget 9:29601-29618
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Sun, Xiujie; Gupta, Kshama; Wu, Bogang et al. (2018) Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice. J Biol Chem 293:2841-2849
Horning, Aaron M; Wang, Yao; Lin, Che-Kuang et al. (2018) Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response. Cancer Res 78:853-864
Gong, Siqi; Tomusange, Khamis; Kulkarni, Viraj et al. (2018) Anti-HIV IgM protects against mucosal SHIV transmission. AIDS 32:F5-F13
Soteros, Breeanne M; Cong, Qifei; Palmer, Christian R et al. (2018) Sociability and synapse subtype-specific defects in mice lacking SRPX2, a language-associated gene. PLoS One 13:e0199399

Showing the most recent 10 out of 989 publications